SALVAGE CRYOABLATION;
RADIATION-THERAPY;
SIGNAL INTENSITY;
CRYOTHERAPY;
FAILURE;
RADIOTHERAPY;
TISSUE;
D O I:
10.1148/radiol.13121291
中图分类号:
R8 [特种医学];
R445 [影像诊断学];
学科分类号:
1002 ;
100207 ;
1009 ;
摘要:
Purpose: To assess the feasibility of magnetic resonance (MR) imaging-guided focal cryoablation in patients with locally recurrent prostate cancer after radiation therapy. Materials and Methods: This was a prospective study, and informed consent was obtained from all patients. Ten consecutive patients with histopathologically proved recurrent prostate cancer after radiation therapy, without evidence of distant metastases, were treated while under general anesthesia in a 1.5-T MR unit. A urethral warmer was inserted. Cryoneedles were transperineally inserted under real-time MR imaging. Then, a rectal warmer was inserted. Ice ball growth was continuously monitored under MR imaging guidance. Two freeze-thaw cycles were performed. Follow-up consisted of a visit to the urologist, measurement of prostate-specific antigen level, and multiparametric MR imaging at 3, 6, and 12 months. Potential complications were recorded. Results: All patients were successfully treated. In one patient, the urethral warmer could not be inserted and the procedure was cancelled. Two months later, the procedure was successfully repeated. Another patient had urinary retention. Follow-up data were available for all patients. A local recurrence or remnant tumor was found in two patients after 6 months and in another patient after 12 months. These three patients underwent successful retreatment with MR imaging-guided focal cryoablation. Conclusion: MR imaging-guided focal cryoablation of recurrent prostate cancer after radiation therapy is feasible and safe. Initial results are promising; however, longer follow-up is needed and more patients must be studied. (c) RSNA, 2013
机构:
Univ Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Dept Urol, Los Angeles, CA 90095 USAUniv Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Dept Urol, Los Angeles, CA 90095 USA
Finley, David S.
;
Pouliot, Frederic
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Dept Urol, Los Angeles, CA 90095 USAUniv Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Dept Urol, Los Angeles, CA 90095 USA
Pouliot, Frederic
;
Miller, David C.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48106 USA
Univ Michigan, Sch Med, VA Ctr Clin Management Res, Ann Arbor, MI 48106 USAUniv Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Dept Urol, Los Angeles, CA 90095 USA
Miller, David C.
;
Belldegrun, Arie S.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Dept Urol, Los Angeles, CA 90095 USAUniv Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Dept Urol, Los Angeles, CA 90095 USA
机构:
Univ Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Dept Urol, Los Angeles, CA 90095 USAUniv Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Dept Urol, Los Angeles, CA 90095 USA
Finley, David S.
;
Pouliot, Frederic
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Dept Urol, Los Angeles, CA 90095 USAUniv Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Dept Urol, Los Angeles, CA 90095 USA
Pouliot, Frederic
;
Miller, David C.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48106 USA
Univ Michigan, Sch Med, VA Ctr Clin Management Res, Ann Arbor, MI 48106 USAUniv Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Dept Urol, Los Angeles, CA 90095 USA
Miller, David C.
;
Belldegrun, Arie S.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Dept Urol, Los Angeles, CA 90095 USAUniv Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Dept Urol, Los Angeles, CA 90095 USA